667 related articles for article (PubMed ID: 20679668)
1. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of eptifibatide versus abciximab in primary percutaneous coronary intervention in patients with acute ST-segment elevation myocardial infarction: results of the EVA-AMI Trial.
Zeymer U; Margenet A; Haude M; Bode C; Lablanche JM; Heuer H; Schröder R; Kropff S; Bourkaib R; Banik N; Zahn R; Teiger E
J Am Coll Cardiol; 2010 Aug; 56(6):463-9. PubMed ID: 20670755
[TBL] [Abstract][Full Text] [Related]
3. Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty.
Beeres SL; Oemrawsingh PV; Warda HM; Bechan R; Atsma DE; Jukema JW; van der Wall EE; Schalij MJ
Catheter Cardiovasc Interv; 2005 Aug; 65(4):478-83. PubMed ID: 15973655
[TBL] [Abstract][Full Text] [Related]
4. Comparison of abciximab versus eptifibatide during percutaneous coronary intervention in ST-segment elevation myocardial infarction (from the HORIZONS-AMI trial).
Singh HS; Dangas GD; Guagliumi G; Yu J; Witzenbichler B; Kornowski R; Grines C; Gersh B; Dudek D; Mehran R; Stone GW
Am J Cardiol; 2012 Oct; 110(7):940-7. PubMed ID: 22748356
[TBL] [Abstract][Full Text] [Related]
5. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).
Akerblom A; James SK; Koutouzis M; Lagerqvist B; Stenestrand U; Svennblad B; Oldgren J
J Am Coll Cardiol; 2010 Aug; 56(6):470-5. PubMed ID: 20670756
[TBL] [Abstract][Full Text] [Related]
6. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
7. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
[TBL] [Abstract][Full Text] [Related]
8. Preservation of myocardial microcirculation during mechanical reperfusion for myocardial ischemia with either abciximab or eptifibatide.
Stoupakis G; Orlando J; Kalia H; Skurnick J; Saric M; Arora R
J Invasive Cardiol; 2003 Sep; 15(9):476-80. PubMed ID: 12947204
[TBL] [Abstract][Full Text] [Related]
9. Eptifibatide vs abciximab as adjunctive therapy during primary percutaneous coronary intervention for acute myocardial infarction.
Raveendran G; Ting HH; Best PJ; Holmes DR; Lennon RJ; Singh M; Bell MR; Long KH; Rihal CS
Mayo Clin Proc; 2007 Feb; 82(2):196-202. PubMed ID: 17290727
[TBL] [Abstract][Full Text] [Related]
10. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Leoncini M; Toso A; Dabizzi RP
Int J Cardiol; 2006 Mar; 108(1):36-42. PubMed ID: 15927285
[TBL] [Abstract][Full Text] [Related]
11. Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Shen J; Zhang Q; Zhang RY; Zhang JS; Hu J; Yang ZK; Zheng AF; Zhang X; Shen WF
Coron Artery Dis; 2008 Jun; 19(4):271-7. PubMed ID: 18480672
[TBL] [Abstract][Full Text] [Related]
12. Short-term comparative outcomes associated with the use of GP IIb/IIIa antagonists in patients undergoing coronary intervention.
Kimmelstiel C; Phang R; Rehman A; Rand W; Miele R; Rhofiry J; MacIsaac DA; Gouveia W; Denier D; Becker RC
J Thromb Thrombolysis; 2001 May; 11(3):203-9. PubMed ID: 11577258
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study.
Prati F; Petronio S; Van Boven AJ; Tendera M; De Luca L; de Belder MA; Galassi AR; Imola F; Montalescot G; Peruga JZ; Barnathan ES; Ellis S; Savonitto S;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1284-91. PubMed ID: 21232723
[TBL] [Abstract][Full Text] [Related]
14. Early initiation of eptifibatide in the emergency department before primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results of the Time to Integrilin Therapy in Acute Myocardial Infarction (TITAN)-TIMI 34 trial.
Gibson CM; Kirtane AJ; Murphy SA; Rohrbeck S; Menon V; Lins J; Kazziha S; Rokos I; Shammas NW; Palabrica TM; Fish P; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):668-75. PubMed ID: 16996831
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary interventions.
Midei MG; Coombs VJ; Lowry DR; Drossner MN; Prewitt KC; Wang JC; Loughrey MB; Gottlieb SO
Cardiology; 2007; 107(3):172-7. PubMed ID: 16940721
[TBL] [Abstract][Full Text] [Related]
16. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
17. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry.
Dudek D; Siudak Z; Janzon M; Birkemeyer R; Aldama-Lopez G; Lettieri C; Janus B; Wisniewski A; Berti S; Olivari Z; Rakowski T; Partyka L; Goedicke J; Zmudka K;
Am Heart J; 2008 Dec; 156(6):1147-54. PubMed ID: 19033011
[TBL] [Abstract][Full Text] [Related]
18. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
[TBL] [Abstract][Full Text] [Related]
19. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial.
Bolognese L; Falsini G; Liistro F; Angioli P; Ducci K; Taddei T; Tarducci R; Cosmi F; Baldassarre S; Burali A
J Am Coll Cardiol; 2006 Feb; 47(3):522-8. PubMed ID: 16458130
[TBL] [Abstract][Full Text] [Related]
20. Long-term results following switch from abciximab to eptifibatide during percutaneous coronary intervention.
Clin Cardiol; ; . PubMed ID: 21089113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
